The uterine fibroid embolization devices market size has grown strongly in recent years. It will grow from $5.62 billion in 2024 to $5.93 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing incidence of uterine fibroids, preference for non-surgical alternatives, awareness and education initiatives, focus on women's health, shift towards outpatient procedures, physician training programs.
The uterine fibroid embolization devices market size is expected to see steady growth in the next few years. It will grow to $7.04 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to increasing awareness of non-invasive treatments, global expansion of healthcare services, rise in female healthcare initiatives, integration with multidisciplinary care, expansion of outpatient services. Major trends in the forecast period include increasing adoption of minimally invasive procedures, advancements in embolic agents, personalized treatment approaches, focus on outpatient ufe procedures, integration of imaging technologies, research on bioresorbable embolic agents.
The increasing demand for minimally invasive surgeries is expected to drive the growth of the uterine fibroid embolization device market. Minimally invasive surgeries involve using small incisions or natural body openings to access and treat internal organs, tissues, or structures, minimizing trauma to the patient's body. Uterine fibroid embolization devices play a crucial role in these procedures by effectively treating uterine fibroids while keeping invasiveness to a minimum. These specialized devices are designed to use small incisions, reducing the impact on surrounding tissues, and catering to the rising preference for less invasive medical treatments, ultimately improving patient outcomes. For example, in August 2023, The Aesthetic Society, a US-based organization in plastic surgery and cosmetic medicine, reported that Americans spent over $11.8 billion on aesthetic procedures, marking a 2% increase from the previous year. Thus, the growing demand for minimally invasive surgeries is driving the expansion of the uterine fibroid embolization device market.
The growing aging population is also expected to contribute to the expansion of the uterine fibroid embolization devices market. The aging population, representing individuals aged 65 years and older, benefits from uterine fibroid embolization devices as a minimally invasive alternative to surgery for addressing symptomatic fibroids. This demographic experiences relief from symptoms such as excessive bleeding and pelvic pain through these devices. According to the World Health Organization's October 2022 report, the global population aged 60 years and older reached 1.4 billion in 2022, and by 2050, it is projected to double to 2.1 billion. Therefore, the increasing aging population acts as a driver for the uterine fibroid embolization devices market.
Major companies in the uterine fibroid embolization device market are focusing on developing innovative products such as the TruClear system to address the growing demand for minimally invasive treatments for uterine fibroids, aiming to enhance safety and efficacy. The TruClear system, launched by Medtronic Private Limited in November 2022, is a mechanical hysteroscopic tissue removal system used for treating intrauterine abnormalities. It features a flexible catheter inserted through the cervix into the uterus, incorporating a spinning nitinol wire loop, continuous inflow and outflow, integrated suction, and high-definition imaging, contributing to the precision and safety of uterine fibroid treatment.
In October 2024, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. Through this acquisition, Hologic seeks to expand its range of minimally invasive treatment options for women's health, with a focus on managing uterine fibroids and heavy menstrual bleeding. Gynesonics Inc. is a US-based medical technology company specializing in the development of minimally invasive solutions for treating symptomatic uterine fibroids.
Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation.
North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uterine fibroid embolization device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The uterine fibroid embolization device market consists of revenues earned by entities by provide services such as minimally invasive procedures, non-invasive procedures, minimally invasive procedures, radiofrequency ablation, medication and hormonal therapy, and embolization procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The uterine fibroid embolization device market also includes sales of medications, hysteroscopic devices, laparoscopic devices, radiofrequency ablation devices, endometrial ablation devices, hysterectomy devices, and robotic surgical systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
A uterine fibroid embolization device is a medical device used in the treatment of noncancerous tumors, specifically uterine fibroids, through a minimally invasive procedure. Uterine fibroids are benign growths in the uterus, and this device functions by restricting the blood supply to these fibroids, causing them to shrink and ultimately disappear.
The main types of technologies associated with uterine fibroid embolization devices include surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. Surgical techniques involve specific methods and procedures employed by medical professionals. These devices are utilized in various treatment modes, including invasive, minimally invasive, and non-invasive treatments. Additionally, they find application in diverse healthcare settings such as hospitals, clinics, and ambulatory surgical centers.
The uterine fibroid embolization device market research report is one of a series of new reports that provides uterine fibroid embolization device market statistics, including uterine fibroid embolization device industry global market size, regional shares, competitors with a uterine fibroid embolization device market share, detailed uterine fibroid embolization device market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid embolization device industry. This uterine fibroid embolization device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Uterine Fibroid Embolization Device Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on uterine fibroid embolization device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for uterine fibroid embolization device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uterine fibroid embolization device market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Technology: Surgical Techniques; Laparoscopic Techniques; Ablation Techniques; Embolization Techniques2) By Mode Of Treatment: Invasive Treatment; Minimally Invasive Treatment; Non-Invasive Treatment
3) By End User: Hospitals; Clinics; Ambulatory Surgical Center
Subsegments:
1) By Surgical Techniques: Open Surgery; Myomectomy2) By Laparoscopic Techniques: Laparoscopic Myomectomy; Laparoscopic Hysterectomy
3) By Ablation Techniques: Radiofrequency Ablation; Microwave Ablation; Cryoablation
4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE); Uterine Artery Embolization (UAE)
Key Companies Mentioned: Johnson and Johnson Pvt Ltd.; Abbott Laboratories; Medtronic plc.; Siemens Healthineers Ltd.; Koninklijke Philips N.V.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Uterine Fibroid Embolization Device market report include:- Johnson and Johnson Pvt Ltd.
- Abbott Laboratories
- Medtronic plc.
- Siemens Healthineers Ltd.
- Koninklijke Philips N.V.
- Stryker Corporation
- Boston Scientific Corporation
- GE HealthCare Technologies Inc.
- Olympus Corporation
- Terumo Corporation
- Smith and Nephew plc.
- Ethicon Inc.
- Hologic Inc.
- CooperSurgical Inc.
- Ferring B.V.
- Cook Medical Inc.
- Karl Storz GmbH
- Merit Medical Systems
- CONMED Corporation
- Amsino International Inc.
- Lumenis Ltd.
- Richard Wolf GmbH
- BTG International Ltd.
- Healthium MedTech Pvt. Ltd.
- INSIGHTEC Ltd.
- Hironic Co.Ltd
- Minerva Surgical Inc.
- Gynesonics Inc.
- Advanced Surgical Concepts PLLC
- Hitachi Medical Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 5.93 Billion |
Forecasted Market Value ( USD | $ 7.04 Billion |
Compound Annual Growth Rate | 4.4% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |